<DOC>
	<DOCNO>NCT01819402</DOCNO>
	<brief_summary>Excess visceral fat associate chronic systemic inflammation cardiovascular complication . Pioglitazone report variably influence visceral fat volume , effect metabolic activity visceral fat remain uncharacterized . To evaluate effect pioglitazone glucose metabolism fat tissue use 18F-fluorodeoxyglucose ( FDG ) -positron emission tomography ( PET ) compute tomography ( CT ) imaging .</brief_summary>
	<brief_title>Pioglitazone Decreases Visceral Fat Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Subjects age 35 85 year Subjects impair glucose tolerance type 2 diabetes Subjects insulin treatment Subjects uncontrolled diabetes , hypertension , symptomatic coronary artery disease , symptomatic cerebrovascular disease Subjects take three antidiabetic medication Subjects take antiplatelet , statin , antidiabetic agent , thiazolidinediones within 8 week prior randomization Subjects cardiac failure ( New York Heart Association Class &gt; III ) leave ventricular dysfunction ( LVEF &lt; 40 % ) Subjects systemic disorder active inflammatory , liver , renal , hematopoietic , malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>visceral fat metabolism ; FDG-PET/CT ; pioglitazone ; glimepiride ; adiponectin</keyword>
</DOC>